Credit, REUTERS/Hannah Beier/Illustration

The National Health Surveillance Agency (Anvisa) approved this Wednesday (4/11) the tablet version of Wegovy, a medicine for obesity from Danish pharmaceutical company Novo Nordisk.

It is the first oral medication in the class of GLP-1 agonists, the same as the so-called "weight loss pens", released in the country to treat obesity and overweight.

The tablet has the same active ingredient as the pen, semaglutide. The difference is that it is taken once a day instead of once a week.

"The arrival of a GLP-1 tablet represents a new tool that will increasingly expand the possibilities of medications that can be used in different patient profiles", says endocrinologist Cynthia Valério, president-elect of Abeso (Brazilian Association for the Study of Obesity and Metabolic Syndrome).

There is still no price or release date in Brazil. In a press release, Novo Nordisk only says that the tablet should reach Brazilian pharmacies "in the next few quarters".

BBC News Brasil asked the company what the launch and price forecast was, but had no response until the publication of this report.

Abroad, the tablet has been on sale in the United States since January. It then reached the United Arab Emirates, the United Kingdom and Germany.

What's missing for the pill to reach Brazilian pharmacies

Anvisa's approval is the first step.

End of Most read

Before reaching the shelves, the medicine must have a maximum price defined by the Medicines Market Regulation Chamber (CMED), a federal government body that sets the ceiling price for all medicines sold in the country.

Only after that can the company start selling. BBC News Brasil also asked Novo Nordisk if the price request had already been made to CMED, and is awaiting a response.

Novo Nordisk requested registration of the tablet from Anvisa on January 30 of this year. The decision was published in the Official Gazette of the Union through Resolution 4,249/2026.

The medicine is recommended for adults with obesity, that is, with a body mass index (BMI) equal to or greater than 30. It is also valid for overweight adults (BMI between 27 and 30) who have at least one disease associated with weight, such as hypertension or type 2 diabetes. In all cases, it should be used together with changes in diet and physical activity.

Where is the tablet already sold and how much does it cost

Watch news from Brazil and the world on the BBC World Service

Download here

End of app promotion

The United States was the first country to approve the pill, in December 2025. Approval was from the Food and Drug Administration (FDA), the American drug regulatory agency. Sales started on January 5th. For those who pay out of pocket, the price ranges from US$149 (R$816) per month for the initial dose to US$299 (R$1,600) for higher doses.

According to Novo Nordisk, more than 7 million prescriptions for the pill have been dispensed in the United States since its launch.

In June, the United Arab Emirates became the first country outside the United States to sell the drug. In the United Kingdom, the local regulatory agency approved the pill in June and sales began in July in private pharmacies. For now, the medicine is not offered by the British public health system, the NHS.

The European Union approved the pill in July, after a favorable opinion from the European Medicines Agency (EMA). Germany was the first country in the bloc to sell the medicine, starting September 1st. The tablet was also approved in Bahrain.

Novo Nordisk says it intends to bring the tablet to other countries in the coming months.

How the medicine works and why the pill dose is higher

Semaglutide mimics GLP-1, a hormone that the intestine releases after meals. It signals to the brain that the body has already received food, which reduces hunger, and makes the stomach empty more slowly, which prolongs the feeling of satiety.

When the medicine is swallowed, much of the substance is lost in the digestive system before reaching the blood. That's why the tablet dose is much higher: 25 mg per day in the maintenance phase, versus 2.4 mg per week with the pen.

Treatment starts with 1.5 mg, and the dose increases little by little, going through 4 mg and 9 mg until reaching 25 mg. The tablet should be taken on an empty stomach, with little water. After that, you need to wait at least 30 minutes to eat, drink or take other medicines.

According to Anvisa, those who use the pen will be able to switch to the tablet, and those who use the tablet will be able to switch to the pen, when the doctor deems it appropriate.

Credit, Ben Birchall/PA Archive/PA Images

What did the study that supported the approval show?

The approval was mainly based on the OASIS 4 study, published in the scientific journal The New England Journal of Medicine. 307 adults without diabetes, obesity or overweight and an associated disease participated, and the results were measured after 64 weeks.

In the group that took the pill, the average weight loss was 13.6%. In the group that received placebo, it was 2.2%. Almost a third of participants who took the pill lost 20% of their weight or more.

Novo Nordisk says weight loss with the tablet is similar to that achieved with the 2.4 mg pen. According to Anvisa, the treatment also improved several markers of the participants' cardiovascular and metabolic health.

The most common side effects were gastrointestinal, such as nausea and diarrhea. They affected 74% of those who took the pill, compared to 42% in the placebo group, and were generally mild or moderate. Around 7% of participants who took the medicine stopped treatment because of adverse effects, compared to 6% in the placebo group.

What changes in relation to Rybelsus, generics and the competing pill

Brazil already had a semaglutide tablet, Rybelsus, also from Novo Nordisk. It is indicated for type 2 diabetes, in smaller doses, and not to treat obesity.

The tablet arrives in a market that changed in 2026. The patent for semaglutide fell in Brazil on March 20, and, since August, Anvisa has already approved generic versions of injectable semaglutide.

By law, generics must cost at least 35% less than the reference medicine.

Novo's main competitor is Foundayo (orforglipron), a daily obesity pill from American Eli Lilly, maker of Mounjaro. Foundayo was approved in the United States in April, but is not yet registered in Brazil.

According to endocrinologist Cynthia Valério, the oral version tends to benefit those who do not want to use an injection, those who prefer to take the medicine every day instead of once a week and those who have difficulty storing their pen, for example because they travel a lot.

The tablet, unlike the pen, does not need to be kept in a refrigerated environment.

She states that the tablet can make it easier to start treatment and gradually increase the dose in patients who use many other medications or have several illnesses. This allows you to better monitor side effects and tolerance to the medication.

“Our biggest challenge today is long-term adherence and sustained weight loss,” says the doctor. Anyone who interrupts treatment loses the benefits they have achieved.

She warns that the pill will not have the expected effect if it is taken together with another medicine, with a liquid other than water or without respecting the fasting period. “It ends up being a waste of energy, money, and the patient’s time without a good response,” he says. "Medical monitoring is always necessary."

For Valério, ensuring access to obesity treatment, whether through the SUS or health plans, is essential. "We understand that today we still have this great challenge of incorporating these technologies", he says.

She assesses that, at the beginning, the pill should not be widely accessible, and states that Abeso will fight for new therapies to be offered both in the SUS and in supplementary health.

Discover more

Watch

End of Watch

Why the use of slimming pens is affecting sales of beauty products, according to L'Oreal

Can weight loss medications be considered doping in sport?

When should Ozivy, a competitor to Ozempic made in Brazil, cost — and when will the pen reach pharmacies

Top news

5 reasons for Trump's party's disaster in the US elections

Who is Abdul El-Sayed, the first Muslim elected senator in the USA

Talarico, the religious Democrat who spoke of a 'non-binary' God and swept conservative Texas

read more

Most clicked